Liver cell injection trial offers hope for cirrhosis patients
NCT ID NCT07488546
First seen Apr 13, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This early-stage trial tests a new cell therapy called HCL001 in 39 adults with decompensated cirrhosis, a serious liver condition. The study aims to find a safe dose and see if the treatment can improve liver function over 48 weeks. Participants receive a single injection of cells, with doses gradually increased to ensure safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DECOMPENSATED CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospita
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.